top of page

Clinical Evaluation and PMCF: Article 61 of the Medical Device Regulation, Annex XIV Parts A and B

12 hours ago
9 min read
Klinik değerlendirme ve PMCF planı Tıbbi Cihaz Yönetmeliği Ek XIV

SUMMARY

Clinical evaluation is the demonstration, by means of clinical data, of conformity of the device with the general safety and performance requirements. Article 61 and Annex XIV of the Medical Device Regulation (Tıbbi Cihaz Yönetmeliği) regulate this process as an obligation of the manufacturer.

In this article we give the paragraphs of Article 61, the clinical evaluation plan in Annex XIV Part A and the post-market clinical follow-up (PMCF) in Part B, quoting the Regulation word for word.

For the ÜTS registration of your medical device: Medical Device ÜTS Registration Consultancy

Contents

1. The Manufacturer Determines the Level of Clinical Evidence

Medical Device Regulation Article 61, first paragraph:

“The manufacturer shall specify and justify the level of clinical evidence necessary to demonstrate conformity with the general safety and performance requirements. That level of clinical evidence shall be appropriate in view of the characteristics of the device and its intended purpose. To that end, manufacturers shall plan, conduct and document a clinical evaluation in accordance with this Article and Part A of Annex XIV.”

Point 2 of Annex XIV ties the depth of the evaluation to the risk of the device:

“The depth and extent of the clinical evaluation shall be proportionate and appropriate to the nature, classification, intended purpose and risks of the device in question, as well as to the manufacturer's claims in respect of the device.”

For the class of the device, see our article on MDR risk class.

2. The Three Bases of Clinical Evaluation

“(3) Clinical evaluation shall follow a defined and methodologically sound procedure based on:”

  • “a) a critical evaluation of the relevant scientific literature currently available relating to the safety, performance, design characteristics and intended purpose of the device, where there is demonstration of equivalence of the device to the device to which the data relate, in accordance with point 3 of Annex XIV, and the data adequately demonstrate compliance with the relevant general safety and performance requirements.”

  • “b) a critical evaluation of the results of all available clinical investigations, taking duly into consideration whether the investigations were performed under Articles 62 to 79, the measures adopted by the Commission and Annex XV.”

  • “c) a consideration of currently available alternative treatment options for that purpose, if any.”

According to point 2 of Annex XIV, the evaluation takes into account both favourable and unfavourable data:

“The clinical evaluation shall be thorough and objective, and take into account both favourable and unfavourable data.”

3. Annex XIV Part A: Clinical Evaluation Plan

According to item (a) of point 1 of Annex XIV, the plan includes, as a minimum:

  • “- an identification of the general safety and performance requirements that require support from relevant clinical data;”

  • “- a specification of the intended purpose of the device;”

  • “- a clear specification of intended target groups with clear indications and contra-indications;”

  • “- a detailed description of intended clinical benefits to patients with relevant and specified clinical outcome parameters;”

  • “- a specification of methods to be used for examination of qualitative and quantitative aspects of clinical safety with clear reference to the determination of residual risks and side-effects;”

  • “- a list and specification of parameters to be used to determine, based on the state of the art in medicine, the acceptability of the benefit-risk ratio for the various indications and for the intended purpose or purposes of the device;”

In the continuation of the same point, the manufacturer identifies the available data and the gaps in evidence through a literature search:

“b) identify available clinical data relevant to the device and its intended purpose and any gaps in clinical evidence through a systematic scientific literature review,”

“ç) generate, through properly designed clinical investigations in accordance with the clinical development plan, the new or additional clinical data necessary to address outstanding issues,”

For the clinical investigation itself, see our article on clinical investigation and investigational devices.

4. Equivalence: Technical, Biological and Clinical Characteristics

Point 3 of Annex XIV:

“3. Clinical evaluation may be based on clinical data relating to a device for which equivalence to the device in question can be demonstrated. The following technical, biological and clinical characteristics shall be taken into consideration for the demonstration of equivalence:”

“The characteristics listed in the first paragraph shall be similar to such an extent that there would be no clinically significant difference in the safety and clinical performance of the device. Considerations of equivalence shall be based on proper scientific justification. It shall be clearly demonstrated that manufacturers have sufficient levels of access to the data relating to devices with which they are claiming equivalence in order to justify their claims of equivalence.”

For a manufacturer demonstrating equivalence to a device it does not itself manufacture, the fifth paragraph of Article 61 requires two additional conditions:

  • “a) there is in place a contract between the two manufacturers that explicitly allows the manufacturer of the second device full access to the technical documentation on an ongoing basis,”

  • “b) the original clinical evaluation has been performed in compliance with the requirements of this Regulation,”

“and the manufacturer provides clear evidence thereof to the notified body.”

5. Clinical Investigation for Class III Devices and Implants

Article 61, fourth paragraph, item (a):

“a) For implantable devices and class III devices, clinical investigations shall be performed unless all of the following conditions are met:”

  • “1) the device has been designed by modifications of a device already marketed by the same manufacturer.”

  • “2) the manufacturer has demonstrated that the modified device is equivalent to the marketed device, in accordance with point 3 of Annex XIV, and this demonstration has been endorsed by the notified body.”

  • “3) the clinical evaluation of the marketed device is sufficient to demonstrate conformity of the modified device with the relevant safety and performance requirements.”

“b) Where no clinical investigation is required under this paragraph, the notified body confirms that the post-market clinical follow-up plan is appropriate and includes post-market studies to demonstrate the safety and performance of the device.”

The sixth paragraph lists the devices to which this obligation does not apply. Item (b):

“b) to sutures, staples, dental fillings, dental braces, tooth crowns, screws, wedges, plates, wires, pins, clips and connectors for which the clinical evaluation is based on sufficient clinical data and is in compliance with the relevant product-specific common specification, where available.”

“(7) Cases where the fourth paragraph is not applied by virtue of the sixth paragraph are justified by the manufacturer in the clinical evaluation report and by the notified body in the clinical evaluation assessment report.”

6. Demonstrating Conformity by Non-Clinical Methods

Article 61, ninth paragraph:

“(9) Without prejudice to the fourth paragraph, where the demonstration of conformity with general safety and performance requirements based on clinical data is not deemed appropriate, adequate justification for any such exception shall be based on;”

  • “a) the results of the manufacturer's risk management,”

  • “b) an assessment of the details of the interaction between the device and the human body, the intended clinical performance and the manufacturer's claims.”

“In such a case, the manufacturer shall duly substantiate in the technical documentation referred to in Annex II why it considers a demonstration of conformity with the general safety and performance requirements based on the results of non-clinical testing methods alone, including performance evaluation, bench testing and pre-clinical evaluation, to be adequate.”

For products in Annex XVI without a medical purpose, performance is demonstrated in place of clinical benefit under the eighth paragraph. For details, see our article on Annex XVI products without a medical purpose.

7. Annex XIV Part B: PMCF

Point 5 of Annex XIV defines PMCF:

“5. Post-market clinical follow-up (PMCF) shall be understood to be a continuous process that updates the clinical evaluation referred to in Article 61 and Part A of this Annex and shall be addressed in the manufacturer's post-market surveillance plan.”

Objectives of the PMCF plan (Annex XIV, 6.1):

  • “a) to confirm the safety and performance of the device throughout its expected lifetime.”

  • “b) to identify previously unknown side-effects and monitor the identified side-effects and contra-indications.”

  • “c) to identify and analyse emergent risks on the basis of factual evidence.”

  • “d) to identify possible systematic misuse or off-label use of the device, with a view to verifying the correctness of the intended purpose.”

The plan contains, as a minimum, the following items (Annex XIV, 6.2):

  • “a) the general methods and procedures of the PMCF to be applied, such as gathering of clinical experience gained, feedback from users, screening of scientific literature and of other sources of clinical data.”

  • “b) the specific methods and procedures of PMCF to be applied, such as evaluation of suitable registers or PMCF studies.”

  • “d) the specific objectives to be addressed by the PMCF.”

  • “e) an evaluation of the clinical data relating to equivalent or similar devices.”

“7. The manufacturer shall analyse the findings of the PMCF and document the results in a PMCF evaluation report that shall be part of the clinical evaluation report and the technical documentation.”

PMCF is part of the post-market surveillance plan. For the surveillance system and PSUR, see our article on post-market surveillance and PSUR.

8. Updating and the Clinical Evaluation Report

Article 61, tenth paragraph:

“(10) The clinical evaluation and its documentation shall be updated throughout the life cycle of the device concerned with clinical data obtained from the implementation of the manufacturer's PMCF plan in accordance with Part B of Annex XIV and the post-market surveillance plan referred to in Article 82. For class III devices and implantable devices, the PMCF evaluation report and, if indicated, the summary of safety and clinical performance referred to in Article 32 shall be updated with such data at least annually.”

“(11) The clinical evaluation, its results and the clinical evidence derived from the evaluation shall be documented in a clinical evaluation report as referred to in point 4 of Annex XIV, which shall, except for custom-made devices, be part of the technical documentation referred to in Annex II relating to the device concerned.”

Point 6.1 of Annex II separately lists the clinical evaluation report and plan in the technical documentation:

“c) the clinical evaluation report and its updates and the clinical evaluation plan referred to in the eleventh paragraph of Article 61 and in Part A of Annex XIV,”

For the summary of safety and clinical performance, see our article on the summary of safety and clinical performance (SSCP).

9. Consultation on Clinical Evaluation

Article 54, first paragraph:

“In addition to the procedures applicable under Article 52, a notified body, when performing the conformity assessment of the following devices, shall also follow the procedure regarding the consultation on the clinical evaluation, as specified in point 5.1 of Annex IX or as referred to in point 6 of Annex X, as applicable:”

  • “a) class III implantable devices.”

  • “b) class IIb active devices intended to administer and/or remove a medicinal product, as referred to in point 6.4 of Annex VIII (Rule 12).”

This procedure is part of the conformity assessment carried out by the notified body. The distribution of procedures by class is in our article on selection of the conformity assessment procedure. For registering in ÜTS the documents issued after the conformity assessment, see our article on ÜTS document registration.

10. Frequently Asked Questions

Who determines the level of clinical evidence?

According to the first paragraph of Article 61, the manufacturer determines and justifies it. The level is appropriate in view of the characteristics of the device and its intended purpose.

Is a clinical investigation always mandatory for a class III device?

No. A clinical investigation is not mandatory if all three conditions in the fourth paragraph of Article 61 are met or if the device falls under the exceptions in the sixth paragraph. The exception is justified in the clinical evaluation report.

Can equivalence be claimed to the device of another company?

According to the fifth paragraph of Article 61, it can, if there is a valid contract between the two manufacturers providing ongoing full access to the technical documentation and the original clinical evaluation was performed in compliance with the Regulation. The manufacturer provides clear evidence thereof to the notified body.

How often is the PMCF evaluation report updated?

According to the tenth paragraph of Article 61, for class III and implantable devices, the PMCF evaluation report and, if indicated, the summary of safety and clinical performance are updated at least annually.

Which document is the clinical evaluation report part of?

According to the eleventh paragraph of Article 61, except for custom-made devices, it is part of the technical documentation referred to in Annex II.

For the ÜTS registration of your medical device: Medical Device ÜTS Registration Consultancy

Sources

 
 

Medical Device ÜTS Registration Consultancy

Request an ÜTS registration consultancy quote

Ehlibeyt Mahallesi, Tekstilciler Caddesi No: 35/7 06520 Çankaya / Ankara - TÜRKİYE

Cevizli Mahallesi, Zuhal Caddesi Ritim İstanbul B Blok, No:44 Maltepe / İstanbul - TÜRKİYE

info@medexmedikal.com
+90 505 580 4622
+90 312 389 1354

ÜTS Guides · Legislation Calendar · Glossary · ÜTS Guide Index · Frequently Asked Questions

Services: ÜTS Consultancy · Who Carries Out the ÜTS Registration? · ÜTS Document Registration Consultancy · ÜTS Product Registration Consultancy · Importer ÜTS Registration Consultancy · Sales Centre Authorisation Certificate · EUDAMED Registration Consultancy · MDR/IVDR Declaration of Conformity · Technical File Preliminary Review · Label and Instructions for Use Check · PRRC Service · PMS and PSUR · Clinical Evaluation · EMDN and GMDN Code Determination · Certificate of Free Sale · EUDAMED XML Generator · ÜTS Registration Training · Correction of a Rejected ÜTS Application

KVKK and Privacy Policy | Cookie Policy | Accessibility Statement

© 2026 Medex Kurumsal Danışmanlık Ltd. Şti.

bottom of page
WhatsApp Hemen Ara